Skip to content

US · GRI · BIOTECHNOLOGY

GRI Bio, Inc. (GRI) intrinsic value and stock valuation

$1.12as of 2026-11-21 · Mkt cap 137.44K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

GRI Bio, Inc. DCF and intrinsic value

InvestorsCraft values GRI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GRI’s statements →

GRI Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology La Jolla, CA 92037 gribio.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-11.96M
20182025
Free cash flow
-$-10.19M
20182025
Total equity
$6.01M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$22.5M$0.00$0.00$0.00
Operating income-$-11.98M-$-8.23M-$-11.39M-$-2.24M-$-9.26M
Net income-$-11.96M-$-8.21M-$-13.04M-$-3.22M-$-9.3M
EPSd-$-119.6M-$-821M——-$-930M
Operating cash flow-$-10.19M-$-8.61M-$-8.99M-$-1.08M-$-850K
Capital expenditure-$0.00$0.00-$-10K-$0.00$0.00
Free cash flow-$-10.19M-$-8.61M-$-9M-$-1.09M-$-850K
Total assets$8.67M$5.74M$2.96M$380K$220K
Total debt$70K$120K$10K$670K$3.61M
Net debt-$-8.16M-$-4.91M-$-1.79M$660K$3.52M
Total equity$6.01M$4.03M$260K-$-1.62M-$-4.72M
Cash and short-term investments$8.23M$5.03M$1.81M$10K$90K
Income statement
20252024202320222021
Revenue$0.00$22.5M$0.00$0.00$0.00
Cost of revenue$0.00$0.00$60K$50K$70K
Gross profit-$0.00-$0.00-$-60K-$-50K-$-70K
Research and development expenses$6.82M$3.77M$3.23M$240K$5.19M
Selling, general and administrative expenses$5.16M$4.46M$8.1M$1.95M$4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$12M$8.23M$11.3M$2.19M$9.19M
Cost and expenses$12M$8.23M$11.4M$2.24M$9.26M
Interest income$20K$30K$0.00$0.00$0.00
Interest expense$0.00$0.00$2.08M$650K$20K
Depreciation and amortization$0.00$0.00$60K$50K$70K
Ebitda-$-11.97M-$-8.2M-$-10.9M-$-2.51M-$-9.21M
Operating income-$-11.98M-$-8.23M-$-11.39M-$-2.24M-$-9.26M
Total other income/expenses, net$20K$30K-$-1.65M-$-980K-$-40K
Income before tax-$-11.96M-$-8.21M-$-13.04M-$-3.22M-$-9.3M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-11.96M-$-8.21M-$-13.04M-$-3.22M-$-9.3M
Weighted average shares outstanding$100K$10K$0.00$0.00$10K
Weighted average diluted shares outstanding$100K$10K$0.00$0.00$10K
Balance sheet
20252024202320222021
Cash and short-term investments$8.23M$5.03M$1.81M$10K$90K
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$8.59M$5.62M$2.93M$310K$100K
Property, plant and equipment, net$70K$120K$20K$70K$120K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$70K$120K$20K$70K$120K
Total assets$8.67M$5.74M$2.96M$380K$220K
Accounts payable$1.84M$900K$1.41M$1.29M$60K
Short-term debt$60K$50K$10K$660K$3.55M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.64M$1.64M$2.7M$1.99M$4.88M
Long-term debt$10K$70K$0.00$10K$70K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$10K$70K$0.00$10K$70K
Capital lease obligations$70K$120K$10K$70K$110K
Total liabilities$2.66M$1.71M$2.7M$2.01M$4.94M
Common stock$0.00$0.00$0.00$0.00$350K
Retained earnings-$-51.7M-$-39.74M-$-31.53M-$-18.5M-$-15.28M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$0.00
Total equity$6.01M$4.03M$260K-$-1.62M-$-4.72M
Total investments$0.00$0.00$0.00$0.00$3.81M
Total debt$70K$120K$10K$670K$3.61M
Net debt-$-8.16M-$-4.91M-$-1.79M$660K$3.52M
Cash flow statement
20252024202320222021
Net income-$-11.96M-$-8.21M-$-13.04M-$-3.22M-$-1.56M
Depreciation and amortization$0.00$0.00$0.00$0.00$50K
Stock-based compensation$790K$150K$390K$30K$0.00
Change in working capital$930K-$-450K$1.68M$1.51M$560K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$660K-$-390K$2.16M$900K$50K
Net cash provided by operating activities-$-10.19M-$-8.61M-$-8.99M-$-1.08M-$-850K
Investments in property, plant and equipment-$0.00-$-400K-$-10K-$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$0.00$0.00-$-10K-$0.00$0.00
Common stock issued$15.6M$13.1M$12.3M$0.00$100K
Common stock repurchased-$0.00-$0.00$0.00-$-120K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$13.4M$11.8M$10.8M$1.01M$600K
Net change in cash$3.2M$3.22M$1.8M-$-80K-$-250K
Cash at end of period$8.23M$5.03M$1.81M$10K$90K
Operating cash flow-$-10.19M-$-8.61M-$-8.99M-$-1.08M-$-850K
Capital expenditure-$0.00$0.00-$-10K-$0.00$0.00
Free cash flow-$-10.19M-$-8.61M-$-9M-$-1.09M-$-850K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About GRI Bio, Inc.

        GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

        CEO
        W. Marc Hertz
        Employees
        4
        Beta
        -0.67

        Explore

        Frequently asked questions

        What is the intrinsic value of GRI Bio, Inc. (GRI)?

        InvestorsCraft does not currently publish an intrinsic value for GRI. How the IC value is calculated.

        Is GRI undervalued?

        InvestorsCraft does not publish an undervaluation signal for GRI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.